Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trial
Being biologic-naive, having low baseline inflammatory burden, or strong week 10 filgotinib responses were associated with lower pMCS over 1 year of treatment. FCP <250 µg/g and week 10 pMCS remission may reduce the need for follow-up endoscopy.
Authors
- Corinne Jamoul (ORCID: https://orcid.org/0009-0002-9363-6077)
- Alessandra Oortwijn (ORCID: https://orcid.org/0000-0002-8556-1004)
- Toshifumi Hibi∥ (ORCID: https://orcid.org/0000-0002-6256-1204)
- Tadakazu Hisamatsu (ORCID: https://orcid.org/0000-0002-1178-3536)
- Laurent Peyrin‐Biroulet (ORCID: https://orcid.org/0000-0003-2536-6618)
- Brian G. Feagan (ORCID: https://orcid.org/0000-0002-6914-3822)
- Édouard Louis (ORCID: https://orcid.org/0000-0002-1287-7075)
- Virginia Taliadouros
- Karine Muller
- Stefan Schreiber (ORCID: https://orcid.org/0000-0002-6807-9822)
Institutions
- Western University (CA)
- Inserm (FR)
- University of Liège (BE)
- Kyorin University (JP)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- University Hospital Schleswig-Holstein (DE)
- Galapagos (Netherlands) (NL)
- Kitasato Institute Hospital (JP)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
- Galapagos (Belgium) (BE)
- University of Lübeck (DE)
Publication Details
- Journal
- Digestive and Liver Disease
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.dld.2025.04.036
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00